[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641587":3},{"organization":4,"outcomesModule":7,"designInfo":31,"detailedDescription":11,"studyPopulation":11,"armGroups":37,"interventions":49,"overallOfficials":11,"centralContacts":61,"locations":67,"responsibleParty":79,"collaborators":11,"id":81,"slug":11,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":11,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":88,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":11,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":102,"whyStopped":11,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},{"fullName":5,"class":6},"Zai Lab (Hong Kong), Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9,13,15,17,19,21,23,25,27,29],{"measure":10,"description":11,"timeFrame":12},"Maximum plasma concentration (Cmax)",null,"From Predose to Day 337",{"measure":14,"description":11,"timeFrame":12},"Time to maximum concentration (Tmax)",{"measure":16,"description":11,"timeFrame":12},"Area under the plasma concentration-time curve from time 0 to last quantifiable concentration (AUClast)",{"measure":18,"description":11,"timeFrame":12},"Area under the plasma concentration-time curve from time zero to infinity (AUCinf)",{"measure":20,"description":11,"timeFrame":12},"Apparent terminal elimination half-life (t1\u002F2)",{"measure":22,"description":11,"timeFrame":12},"Apparent total body clearance (CL\u002FF)",{"measure":24,"description":11,"timeFrame":12},"Apparent volume of distribution (Vz\u002FF)",{"measure":26,"description":11,"timeFrame":12},"Steady State Volume of distribution (Vss IV)",{"measure":28,"description":11,"timeFrame":12},"Total Body Clearance (CL IV)",{"measure":30,"description":11,"timeFrame":12},"Absolute bioavailability (F)",{"allocation":32,"interventionModel":33,"interventionModelDescription":11,"primaryPurpose":34,"observationalModel":11,"timePerspective":11,"maskingInfo":35},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":36,"maskingDescription":11,"whoMasked":11},"NONE",[38,43,46],{"label":39,"type":40,"description":11,"interventionNames":41},"ZL-1503 (Intravenous Administration)","EXPERIMENTAL",[42],"Drug: ZL-1503",{"label":44,"type":40,"description":11,"interventionNames":45},"ZL-1503 (Subcutaneous Dose 1)",[42],{"label":47,"type":40,"description":11,"interventionNames":48},"ZL-1503 (Subcutaneous Dose2)",[42],[50,55,58],{"type":51,"name":52,"description":53,"armGroupLabels":54,"otherNames":11},"DRUG","ZL-1503","Healthy volunteers will receive a single intravenous dose of ZL-1503.",[39],{"type":51,"name":52,"description":56,"armGroupLabels":57,"otherNames":11},"Healthy volunteers will receive a single subcutaneous administration at Dose 1.",[44],{"type":51,"name":52,"description":59,"armGroupLabels":60,"otherNames":11},"Healthy volunteers will receive a single subcutaneous administration at Dose 2.",[47],[62],{"name":63,"role":64,"phone":65,"phoneExt":11,"email":66},"ZaiLab Medical Director","CONTACT","+86 021-61632588","ZL-1503-002_StudyTeam@zailaboratory.com",[68],{"facility":69,"status":11,"city":70,"state":70,"zip":11,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":11},"ZaiLab Site 18001","Auckland","New Zealand","NZ",{"type":74,"coordinates":75},"Point",[76,77],174.76349,-36.84853,{"lat":77,"lon":76},{"type":80,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100641587",false,"NCT07658482","A Phase 1 Study to Evaluate Pharmacokinetics, Safety and Tolerability of ZL-1503 in Healthy Volunteers","A Phase 1, Randomized, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-1503 Following a Single Dose of Subcutaneous or Intravenous Administration in Healthy Volunteers.","Inclusion Criteria:\n\n* Healthy male and female volunteers, 18-65 years of age\n* Body mass index (BMI) between ≥ 18.5 and \\\u003C 32.5 kg\u002Fm2\n* Negative pregnancy tests for women of childbearing potential.\n\nExclusion Criteria:\n\n* Significant health issues, such as positive tests for human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B surface antigen (HBsAg), active tuberculosis, immunodeficiencies or autoimmune diseases.\n* History of major metabolic, liver, kidney, hematologic or other significant disorders.\n* Abnormal Electrocardiogram (ECG) findings\n* Clinically relevant abnormal lab results, including low blood counts, or abnormal liver and kidney function.\n* History of drug abuse or addiction within 6 months prior to screening\n* Current smoker or use of any nicotine or tobacco containing products within the last 6 months prior to dosing.\n* Donated \\>500mL blood within 2 months of dosing.",true,"ALL","18 Years","65 Years",{"count":92,"type":93},36,"ESTIMATED","INTERVENTIONAL",[96],"PHASE1","This is a phase 1, single dose, randomized, open-label, parallel-group study to evaluate the pharmacokinetics (PK), safety, tolerability and immunogenicity of ZL-1503 and to explore its PD biomarkers following a single subcutaneous (SC) or intravenous (IV) administration in healthy volunteers.",[99],"Healthy Volunteers",[101],"Healthy volunteers","NOT_YET_RECRUITING","2026-06-18",{"date":105,"type":106},"2026-06-22","ACTUAL",{"date":108,"type":93},"2026-09-03",{"date":110,"type":93},"2027-11-10",{"name":112,"class":6},"Zai Lab (Shanghai) Co., Ltd.",1]